Horizon Discovery and University of Torino Receive Eurostars Award
News Feb 16, 2010
Horizon Discovery (Horizon) and the University of Torino, Department of Oncological Sciences, announced that they have been awarded a three-year Eurostars grant under the EUREKA and EU Seventh Framework Programme for Research and Technological Development.
The grant application entitled “Interrogation of Somatic and Inherited Gene-variations for Human Therapy (INSIGHT)” was ranked first amongst all applications received in the UK and Italy, and third across the entire EU.
The ‘INSIGHT’ program will explore a novel class of inherited and somatic non-coding mutations associated with cancer causation. Once their biological role and mechanisms in cancer have been confirmed or elucidated, these disease models will be made available to the wider research community and profiled (by Horizon) for all known existing cancer drugs that may target these cancer genetic variations, to discover potential new therapeutic options for patients.
Horizon will perform the in vitro gene engineering and drug screening; and Professor Alberto Bardelli will identify other cancer associated SNPs for modeling.
Professor Bardelli is a leader in the field of cancer genetics and therapy and his work is actively leading to the adoption of new and more effective ‘Personalized Medicine’ strategies by pharmaceutical companies and healthcare agencies; in particular his landmark research recently linking mutant K-Ras and other genetic mutations to resistance to novel EGFR-targeted therapies in colon cancer.
The grant which begins in March 2010 is spread over a period of three years and will contribute toward a $1,000,000 program of work that will lead to the marketing by Horizon of a panel of new patient relevant X-MAN™ disease models and the co-ownership of new inventions that will be commercialized via Horizon.
New Inherited Neurodevelopmental Disease DiscoveredNews
Researchers have identified a new inherited neurodevelopmental disease that causes slow growth, seizures and learning difficulties in humans.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE